Topical corticosteroids are the first line medications for treatment of simple contact and allergic dermatitis. In this case, fast clinical response, ease of use of dermatics, and the absence of side effects during short-term treatment are believed to be quite important conditions. These factors affect patients’ life quality and their adherence to therapy. In this context, topical corticosteroid Beloderm Express in the form of spray is very promising. Objective. The objective of the study is to assess the efficacy, usability, and safety of spray containing 0.05% betamethasone in patients with contact (simple or allergic) dermatitis. Material and methods. The study included 50 patients diagnosed with allergic contact dermatitis (L-23) or simple contact dermatitis (L-24). All patients applied spray 2 times a day for 7 days. Efficacy was evaluated during visits: D1 (on the day of treatment), D3 (after 3 days of treatment), D7 (after 7 days of treatment) with allowance for dermatological status index and its components, life quality and questioning the patients about spray usability. Results. When using spray, containing 0.05% betamethasone, in patients with allergic/contact dermatitis, rapid clinically significant effect occurs as evidenced by alleviation of erythema, edema, vesicles, itching, and pain. All examined patients reported convenient application, rapid effect, and the ease of use of the spray. Safety and good tolerability of the drug are evidenced by the absence of adverse events and side effects. Conclusions. Spray containing 0.05% betamethasone (Beloderm Express) is a targeted quick-acting remedy against allergic skin inflammation. It is highly effective and can be used as the drug of choice in patients with allergic or simple contact dermatitis.